The United States is one of only two countries in the world (the other is New Zealand) that allows pharmaceutical companies to advertise prescription drugs directly to consumers. That unique legal status, combined with the fact that these ads actually work, is the core reason your evening news or streaming break feels like a pharmacy tour. In 2024 alone, drug companies spent over $6 billion on TV advertising, with 75 individual brands each investing at least $10 million.
The U.S. Is Nearly Alone in Allowing These Ads
Every other developed nation, from Canada to the UK to Japan, prohibits or heavily restricts advertising prescription medications to the general public. The logic in those countries is straightforward: prescribing decisions should be made by doctors, not influenced by marketing. The U.S. took a different path. The FDA has long permitted pharmaceutical promotion, but the real turning point came in 1997, when the agency relaxed its rules for broadcast advertising. Before that, TV ads for prescription drugs were impractical because regulations essentially required companies to list every risk in full detail on screen. The 1997 guidance allowed advertisers to summarize the major risks and direct viewers to a toll-free number, website, or print ad for the complete information. That change made 60-second drug commercials feasible for the first time, and spending exploded from about $2.1 billion in 1997 to $9.6 billion by 2016.
They Keep Airing Because They Work
Pharmaceutical companies aren’t spending billions out of habit. These commercials measurably change patient behavior. About 30 to 32 percent of patients report asking their doctor about a specific drug after seeing an ad. Of those who bring it up, roughly 39 percent request a particular brand by name.
Here’s the number that really matters to drug companies: when patients do request a specific medication, doctors prescribe it about 39 to 78 percent of the time, depending on the study. Even conservative estimates show that more than half of patients who ask for an advertised drug walk out with a prescription for it. That conversion rate, from a TV spot to an actual sale, makes pharmaceutical advertising enormously profitable compared to almost any other form of marketing.
Most Advertised Drugs Aren’t Breakthroughs
You might assume that the drugs getting the most airtime are revolutionary treatments. They’re generally not. An analysis of television drug advertising found that fewer than one-third of the most heavily advertised medications were rated as having high therapeutic value. Of the roughly $22.3 billion spent on TV drug ads over the period studied, about $15.9 billion went toward products offering only low or modest added benefit over existing treatments. The ads also overwhelmingly promote newer, brand-name drugs rather than low-cost generics that may work just as well.
This makes sense from a business perspective. Generic drugs are cheap and widely known, so there’s little profit in advertising them. New brand-name drugs, especially in competitive categories like autoimmune conditions, diabetes, and weight loss, need to build awareness quickly before patents expire. The advertising budget gets folded into the drug’s price, which is one reason brand-name medications cost so much more than their generic equivalents.
Why the Side-Effect Lists Are So Long
The rapid-fire recitation of side effects isn’t just a quirk of these commercials. It’s a legal requirement. Any TV ad that names a prescription drug and its intended use must include what the FDA calls a “major statement,” covering the most important risks, side effects, and situations where the drug shouldn’t be used. The law requires “fair balance,” meaning the presentation of risks must be reasonably similar in prominence to the presentation of benefits. That doesn’t necessarily mean equal time, but it means the risks can’t be buried or glossed over.
In practice, the side-effect portion takes up a huge chunk of each ad. A content analysis of prescription drug commercials found that the average ad ran about 70 seconds, and the major statement listing risks averaged 33 seconds, nearly half the total runtime. Some risk disclosures ran as long as 73 seconds on their own. This is why you’ll see a 60-second spot where someone joyfully rides a bicycle for 30 seconds while a narrator spends the other 30 listing everything from nausea to serious infections.
A recent FDA rule tightened these requirements further. Drug ads on TV must now present the major statement in “consumer-friendly language” at a pace and volume at least as clear as the rest of the ad. The side effects must appear simultaneously as on-screen text and audio, and the ad can’t include distracting visuals or music during the risk disclosure that might make it harder to absorb. This rule was a direct response to the common tactic of showing upbeat imagery and playing background music while the narrator rattled through serious warnings at high speed.
Why Certain Time Slots Feel Saturated
Drug ads cluster heavily during news programs, daytime TV, and shows with older viewership because pharmaceutical companies are targeting the demographics most likely to use prescription medications. Adults over 50 watch significantly more traditional television than younger age groups and are far more likely to be managing chronic conditions like high blood pressure, diabetes, or arthritis. The ads you see during prime-time network news aren’t random. They’re precisely targeted at the audience most likely to sit in a doctor’s office and ask about what they saw.
Cable news channels are particularly dense with drug ads because their audiences skew older and watch for extended periods. If you’re streaming ad-free content or watching platforms aimed at younger viewers, you’ll encounter far fewer pharmaceutical spots. The perception that “there are so many” often reflects which channels and time slots you’re watching.
The Ongoing Debate
Critics argue that direct-to-consumer advertising drives up drug prices (since companies recoup ad costs through higher prices), pushes patients toward expensive brand-name drugs when cheaper options exist, and puts pressure on doctors to prescribe medications that may not be the best choice. Supporters counter that the ads educate patients about conditions they might not know are treatable, encourage people to seek medical care, and give patients more agency in conversations with their doctors.
Several proposals have circulated in Congress over the years to ban or restrict prescription drug advertising, but the pharmaceutical industry is among the largest lobbying forces in the country, and the TV networks themselves earn billions from these ads. For now, the U.S. remains the world’s outlier, and as long as a 60-second commercial can reliably translate into millions in new prescriptions, the ads aren’t going anywhere.